ABSTRACT

Acute Respiratory Distress Syndrome (ARDS) is a severe medical condition caused due to direct or indirect lung injuries with the highest rate of mortality. Aviptadil is a synthetic form of human vasoactive intestinal peptide and has been used to treat various lung inflammatory conditions, including ARDS. Aviptadil exerts an anti-cytokine effect and increases surfactant production which helps to improve the oxygenation index in ARDS patients. Our case series highlights the role of Aviptadil in the reduction of oxygen requirement and increase in PaO2:FiO2 ratio in moderate to severe ARDS patients.